Total returns on $1000
1Y
- 3M
- 6M
- 1Y
- 3Y
- 5Y
| Fund/benchmark | Change | |
|---|---|---|
| Price | RTW Biotech Opportunities Ltd (Ordinary Share) | +52.25% |
| NAV | RTW Biotech Opportunities Ltd (Ordinary Share) | +25.40% |
| Morningstar's Benchmark | Russell 2000 Biotech Growth | -- |
Announcements
- Monthly Valuation Update and Factsheet
- Corxel completes $287 million Series D-1 financing
- Director/PDMR Shareholding
- GSK to acquire RAPT Therapeutics
- Boston Scientific to acquire Penumbra
- Monthly Valuation Update and Factsheet
- Aktis announces $318 million IPO
- Total Voting Rights
- New investment in Yarrow Bioscience
- Monthly Valuation Update and Factsheet
More ▼
Key statistics
As of last trade RTW Biotech Opportunities Ltd (RTW:LSE) traded at 2.09, -9.92% below its 52-week high of 2.32, set on Jan 14, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Shares outstanding | 326.37m |
|---|---|
| Market cap | 675.59m USD |
| Total assets | 773.51m USD |
| Total expense ratio | -- |
| High | 2.09 |
| Low | 2.09 |
| Previous close | 2.08 |
| Average volume | 328.46k |
|---|---|
| YTD Change | -3.24% |
| Beta | 1.2183 |
| Diluted NAV (est) | 2.37 |
| Diluted NAV (last pub) | 2.37 |
| Premium/Discount | -12.24% |
| Net Gearing | 0.00% |
Data delayed at least 20 minutes, as of Feb 19 2026 08:29 GMT.
More ▼
